Evidence map›Paper›PMID 40593467›Full record

ArticleCell discovery2025

Spatially resolved C1QC

Hangyu Zhang, Libing Hong, Zhen Dong, Shan Xin, Bo Lin, Jinlin Cheng, Weihong Tian, Bin Li, Jing Wang, Xiaoyan Liu and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Single-cell epigenomics of colorectal cancer.Experimental & molecular medicine · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Evolution of SPP1Cell reports. Medicine · 2026
    Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Hangyu Zhang *Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Libing Hong *Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Zhen Dong *Westlake Center for Intelligent Proteomics, Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang, China.ORCID http://orcid.org/0000-0002-3480-3421
Shan Xin *Department of Genetics, Yale School of Medicine, New Haven, USA.ORCID http://orcid.org/0000-0002-4735-0935
Bo LinInnovation Centre for Information, Binjiang Institute of Zhejiang University, Hangzhou, Zhejiang, China.
Jinlin ChengState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Weihong TianChangzhou Third People's Hospital, Changzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu, China.
Bin LiDepartment of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Jing WangInnovation Centre for Information, Binjiang Institute of Zhejiang University, Hangzhou, Zhejiang, China.
Xiaoyan LiuDepartment of Pathology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Chuan LiuDepartment of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Yuzhi JinDepartment of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Yanzhi FengDepartment of lmmunobiology, Yale School of Medicine, New Haven, USA.
Ge SuCollege of Computer Science, Zhejiang University, Hangzhou, Zhejiang, China.
Xuqi SunDepartment of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Qiqi LiuDepartment of Radiation Oncology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Xiaomeng DaiDepartment of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Yang GaoDepartment of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Zhou TongDepartment of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Lulu LiuDepartment of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Xudong ZhuDepartment of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Yi ZhengDepartment of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Peng ZhaoDepartment of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Tiannan GuoWestlake Center for Intelligent Proteomics, Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang, China. guotiannan@westlake.edu.cn.ORCID http://orcid.org/0000-0003-3869-7651
Weijia FangDepartment of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. weijiafang@zju.edu.cn.
Xuanwen BaoDepartment of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. xuanwen.bao@zju.edu.cn.

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82101830National Natural Science Foundation of China (National Science Foundation of China) 82102817National Natural Science Foundation of China (National Science Foundation of China) 82202875National Natural Science Foundation of China (National Science Foundation of China) 82303850National Natural Science Foundation of China (National Science Foundation of China) 82473471National Natural Science Foundation of China (National Science Foundation of China) 92259201Natural Science Foundation of Zhejiang Province (Zhejiang Provincial Natural Science Foundation) 2023C03061Natural Science Foundation of Zhejiang Province (Zhejiang Provincial Natural Science Foundation) LQ23H160029Natural Science Foundation of Zhejiang Province (Zhejiang Provincial Natural Science Foundation) LQ23H160041Natural Science Foundation of Zhejiang Province (Zhejiang Provincial Natural Science Foundation) LQ24H160017Natural Science Foundation of Zhejiang Province (Zhejiang Provincial Natural Science Foundation) LY23H160013
6 · The paper itself

Abstract

Colorectal cancer (CRC), including both microsatellite instability (MSI) and microsatellite stability (MSS) subtypes, frequently exhibits intrinsic resistance to immunotherapy. However, the spatial tumor microenvironment (TME) and its role in distinguishing immunotherapy responders from non-responders remain poorly understood. In this study, spatial multiomics, including imaging mass cytometry (n = 50 in-house), spatial proteomics (n = 50 in-house), and spatial transcriptomics (n = 9 in-house), were employed to elucidate the spatial TME of metastatic CRC (mCRC) patients receiving immunotherapy. These methodologies were integrated with single-cell RNA sequencing (scRNA-seq), bulk RNA-seq, and bulk proteomics for comprehensive analysis and validation. A spatial immune atlas containing 314,774 cells was constructed. We found that C1QC

Identifiers

PMID40593467
PMCPMC12219098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.